Many life sciences companies are working and collaborating tirelessly to develop treatments for COVID-19. At the same time, they must also advance the vaccines and treatments in their pipelines that are essential for so many other health issues.
Overcoming challenges in the life sciences industry
As the life sciences industry works, invests and collaborates tirelessly to fast-track testing and treatment for COVID-19, they must also continue to advance their pipelines and rethink ways of bringing treatments to patients- people depend on it.
Empowering life sciences teams to collaborate and work remotely is paramount. In addition, managing supply chain challenges so basic materials can get to clinical trials and patients and ensuring quality and safety in manufacturing is essential.
The COVID-19 pandemic is not just a short-term crisis. It has long-lasting implications for how people work, how we will treat patients and how companies will operate and be viewed in the world. Life sciences companies can redefine their position on the world stage and set a new standard as trusted, valued partners in the healthcare community.
A game-changing new supply chain network
When the pandemic struck, developing and deploying effective and safe vaccines as quickly as possible was a top priority. Pharmaceutical companies mobilized to create, test and get vaccines out the door to millions of people rapidly and safely. One leading biopharmaceutical company set out to be the first, rapidly developing a mRNA-based drug. Working in parallel they needed to scale up manufacturing and build a new supply chain network at record speed. As drug development progressed it became clear a game-changing new supply chain network was needed to enable lightspeed delivery and safe handling of a unique new cold chain drug. By identifying current state bottlenecks, automation opportunities and continuous improvement opportunities, we’ve helped prepare the company for ongoing vaccine supply, new formulation launches and created a blueprint for rapid future mRNA product launches.
Perhaps more than ever before, the integrity and trust in life sciences companies is on a global stage. It's a once in a generation chance to do things differently.
In this climate of crisis, your responses and actions determine both how you lead in the near-term and how you can pave the way for future progress. Leaders will seize this time to take swift action and proactively prepare the organization to continue to manage its core business while ensuring a continued focus on patient health and treating COVID-19.
As you prepare and plan your response, we'd like to share our latest thinking on how the industry could manage the human and business impact.